Navigation Links
Carvedilol shown to have unique characteristics among beta blockers
Date:11/20/2009

CHAMPAIGN, Ill. In a new study, researchers report that a class of heart medications called beta-blockers can have a helpful, or harmful, effect on the heart, depending on their molecular activity.

The study, which appears in the journal Circulation Research, found that beta-blockers that target both the alpha- and beta-receptors on the heart muscle offer the most benefit to cardiac patients, while those that target only the beta-receptors can actually undermine the structure and function of the heart.

Circulation Research is published by the American Heart Association.

Heart disease is the leading cause of death in the United States. Patients with heart disease usually have higher levels of catecholamines hormones that activate the beta-adrenergic receptors to stimulate cardiac muscle contraction. In this process, the heart initially grows to become a more efficient pump. Unfortunately, the researchers found, this growth also predisposes the heart to eventual failure.

Traditionally, beta-blockers targeting the beta-adrenergic receptors have been utilized as a long-term therapy for heart failure.

Interestingly, blocking adrenergic receptors has been widely used clinically for nearly 50 years without a full understanding of the molecular consequences of these drugs, said co-author and graduate student David Cervantes. Kevin Xiang, a professor of molecular and integrative physiology at the University of Illinois led the study. The research team also included researcher Catherine Crosby.

A previous study in 2003 showed that the beta-blocker carvedilol produced a greater survival benefit than another drug, metoprolol tartrate. Carvedilol targets both the beta- and alpha-adrenergic receptors.

The new study unveiled an elegant intracellular signaling system in which beta-receptor activation modulates alpha-adrenergic signaling. It showed that blocking the beta-receptor alone promotes cardiac remodeling via growth of cardiac fibroblasts induced by alpha-adrenergic receptor signaling. The growth of fibroblasts in the heart further damages the integrity and function of the heart.

This observation suggests that the use of carvedilol in combination with inhibitors of angiotensin-converting enzyme (ACE inhibitors) may be of the greatest benefit to cardiac patients, and has significant clinical implications on which beta-blockers patients should take.

"I think this is really good stuff," Xiang says. "It's a surprise project. It's not what we initially intended looking into. But it's a very nice, elegant study and a very beautiful cellular mechanism. It definitely will help people along the way to understand how to further manipulate this system. Beta blockers are still the most commonly used drug for heart disease."


'/>"/>

Contact: William Gillespie
gillespi@illinois.edu
217-265-0722
University of Illinois at Urbana-Champaign
Source:Eurekalert

Related biology news :

1. Spaceflight shown to alter ability of bacteria to cause disease
2. DNA methylation shown to promote development of colon tumors
3. Chocolate bar shown to lower cholesterol
4. Ultrasound shown to exert remote control of brain circuits
5. Dictyostelium cells shown to lay breadcrumb trail as first step in multicellular formation
6. Twin nanoparticle shown effective at targeting, killing breast cancer cells
7. Widely used virus assay shown unreliable when compared to other methods
8. A unique arrangement for egg cell division
9. Scientists spy enzyme that makes us unique
10. A unique experiment with chlorine -- and a new way of teaching
11. Unique pattern of gene expression can indicate acetaminophen overdose
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... Research and Markets has announced the addition of the "Biometrics ... The report forecasts the biometrics market ... CAGR of 12.28% during the period 2016-2020. The ... inputs from industry experts. The report covers the market landscape and ... a discussion of the key vendors operating in this market. ...
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... HAMILTON, Bermuda , Dec. 5, 2016 ... leading clinical-stage biopharmaceutical company focused on the treatment of ... of intepirdine for the treatment of Alzheimer,s disease will ... Disease (CTAD) Meeting on Friday, December 9, 2016 in ... CTAD will show results of both simple and complex ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... to soon resume cervical and lumbar disc production, company President, Jake Lubinski will ... who are implanting the AxioMed disc in Cologne and Karlsruhe to discuss the ...
(Date:12/5/2016)... NxGen MDx announced today that it brought its NxGen Informed ... been able to improve customer service through shortened turnaround times and at ... , CEO of NxGen MDx. ... A decrease in turnaround times by ... job opportunities at the Grand Rapid headquarters. The NxGen Informed ...
(Date:12/4/2016)... ... December 02, 2016 , ... A proposed five-year extension ... federally funded research and development is welcome news for the photonics community, say ... , As part of the National Defense Authorization Act (NDAA) compromise agreement finalized ...
Breaking Biology Technology: